Ocular manifestations of systemic lupus erythematosus.
Ocular manifestations of lupus are fairly common, may be the presenting feature of the disease and can be sight-threatening. Almost any part of the eye and visual pathway can be affected by inflammatory or thrombotic processes. Ocular pain and visual impairment require urgent assessment by an ophthalmologist. Infection should be excluded. Optic neuritis and ischaemic optic neuropathy may be difficult to distinguish. Scleritis and severe retinopathy require systemic immunosuppression but episcleritis, anterior uveitis and dry eyes can usually be managed with local eye drops. Vaso-occlusive disease, particularly in the presence of antiphospholipid antibodies, requires treatment with anticoagulation and proliferative retinopathy is treated with laser therapy. Hydroxychloroquine rarely causes ocular toxicity at doses under 6.5 mg/kg/day. When this has occurred, it has been associated with more than 5 years of drug exposure.
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham, UK.
R R
RR
Sivaraj
O M
OM
Durrani
A K
AK
Denniston
P I
PI
Murray
Caroline
C
Gordon
D005128:Eye Diseases / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007637:Keratoconjunctivitis / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000175:diagnosis; D008297:Male; D009887:Ophthalmoscopy; D009902:Optic Neuritis / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D015995:Prevalence; D011379:Prognosis; D015356:Retinal Artery Occlusion / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D014792:Visual Acuity